Съществува риск за преждевременно раждане (< 37 седмици), както и за хиперкалиемия при новороденото (честота 8 от 111 новородени, т. е.
In case of in utero exposure, monitoring of the newborn for the potential adverse events of tacrolimus is recommended (in particular effects on the kidneys). There is a risk for premature delivery (< 37 week) as well as for hyperkalaemia in the newborn (incidence 8 of 111 neonates, i. e.